GDF-15 Levels in Risk Stratification in Acute Pulmonary Embolism
NCT ID: NCT03672123
Last Updated: 2023-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
270 participants
OBSERVATIONAL
2018-09-17
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of Different Risk Assessment Strategies in Normotensive Pulmonary Embolism
NCT02843243
Identifying Low-Risk Patients With Pulmonary Embolism
NCT00086151
The Prospective Risk Factor Evaluation & Discovery In CTEPH Study
NCT03470207
Diagnostic Accuracy of Arterial-alveolar Oxygen Gradient in Low Risk Patients With Suspected Pulmonary Embolism
NCT06043726
Short-term Clinical Deterioration After Acute Pulmonary Embolism
NCT03915925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In APE right ventricle failure developing due to ischemia and myocarditis is considered the primary cause of death, however, its pathomechanism has not been fully established yet. Growth differentiation factor 15 (GDF-15) is a chemokine secreted by activated macrophages in response to oxidative stress. It has now been shown that ischemic injury, mechanical stretch, and pro-inflammatory cytokines also stimulate the expression of GDF-15 in cardiac myocytes. The objective of this project is to describe the role of GDF-15 in the pathomechanism of acute right ventricle failure in the setting of acute pulmonary embolism and to verify the hypothesis that higher serum concentrations of GDF-15 are associated with more advanced right ventricle dysfunction and failure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APE with RVD
RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
No interventions assigned to this group
APE without RVD
RVD defined according to ESC criteria
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* APE with symptoms lasting above 14 days before the admission
* acute coronary syndrome, diagnosed pulmonary hypertension
* severe valve disease
* sepsis
* active malignancy
* diagnosed mitochondrial diseases
* chronic kidney disease at least stage 4 (KDIGO)
* pregnancy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Science Center, Poland
UNKNOWN
Medical University of Warsaw
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marta Skowronska
Principal Investigator, Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marta Z Skowronska, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Warsaw
Piotr Pruszczyk, Prof.
Role: STUDY_DIRECTOR
Medical University of Warsaw
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine & Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw
Warsaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GDF-15 APE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.